Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. - Wikidata - awgldk - TriplyDB

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

http://www.wikidata.org/entity/Q34006585

about

Invasive candidiasis as a cause of sepsis in the critically ill patient Central venous catheter (CVC) removal for patients of all ages with candidaemia Micafungin: an evidence-based review of its place in therapy Structure of Protein Geranylgeranyltransferase-I from the Human Pathogen Candida albicans Complexed with a Lipid Substrate Fundament and Prerequisites for the Application of an Antifungal TDM Service Intensive care medicine research agenda on invasive fungal infection in critically ill patients.Safety and pharmacokinetics of repeat-dose micafungin in young infants.Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study Rapid species diagnosis for invasive candidiasis using mass spectrometry ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Population pharmacokinetics of micafungin in neonates and young infants Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Fungal infections in transplant and oncology patients.Breakthrough invasive candidiasis in patients on micafungin.Echinocandins: the newest class of antifungals.Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Canadian clinical practice guidelines for invasive candidiasis in adults.Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.Antifungal clinical trials and guidelines: what we know and do not know Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study Clinical hepatotoxicity associated with antifungal agents.Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study Invasive candidiasis in non-hematological patients.Micafungin in the treatment of invasive candidiasis and invasive aspergillosis Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.Epidemiology and treatment approaches in management of invasive fungal infections Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.

P2860

Q22305429-2E67C835-4B71-4742-B65E-EF865B10B8C5 Q26471135-F7A12BF0-A2C1-4403-AF82-8A22212EB4A3 Q27014780-C2C1758E-E851-46D0-BA13-38B3FE5FE6EE Q27651678-33572D38-2504-42B7-B19D-18E8C07B29F8 Q28085352-81E47DB9-8645-49C5-BE36-756FE1043C50 Q30235457-BD60D080-1F56-4809-8B67-DD63BAD6554D Q30433612-E7C74054-7A07-47B1-B6D3-816EEDA4E28C Q30781344-ED024198-1702-42D5-A467-77C1DB739AB4 Q33527403-AFBC7555-8916-47C5-A923-4EF2A69EBDF5 Q33573788-2A11F2FF-C6FE-43B5-B297-8A17B1CCF836 Q33640559-6B022BB5-ADB3-42C8-9C1E-5972E2DB1E08 Q33798097-74E5F9AD-4763-425B-8260-E14B0AB10CFB Q33816237-C7B94570-5878-4A9D-82B4-F0964F4B3A5A Q33826372-CCA95C03-879D-4774-9FF8-84C32C76CA58 Q33876423-B119D705-B2FF-43A7-810D-2EA4B6834A96 Q33876608-8F399FE7-F6DF-4BF7-8C28-206B6AC0042D Q33876645-9996C658-A784-44B4-B356-818F68C7B5E2 Q33896940-FB1F79B8-F250-4467-BEDA-282B7EDB89CD Q33963538-FE58D805-B7A9-4580-A4F8-696CD5D2F2D7 Q34019188-4794024C-7869-4835-8E2A-576E5B4B0C97 Q34036214-B7A882D0-A5A4-462C-B14C-6ACC9C0279CB Q34045450-39DE7CEC-75C6-4576-9782-E1E1804794A8 Q34151170-8368B198-6EE3-4E58-BD93-E89D9FFD108F Q34237335-D5E4AC97-2283-437C-8708-CC26DF05080D Q34337608-3CDE8C3A-AA66-4E82-9B4B-3935013CF0DF Q34400255-9646FC39-CBC6-4DB0-A9B5-1A70D2FD35D7 Q34505582-F33FE9AD-EBBF-4347-A953-52D3E54BE851 Q34543097-3894E6E2-73A2-457D-9272-7736FB340E0A Q34546811-599770ED-2AA5-44A1-9E77-9D397F84091C Q34775518-254D6659-78EE-43B7-9CEF-3B1E21EE82A4 Q34933267-175775AB-A0C3-48D4-BDF5-E4B9428B57B4 Q34978993-0E1CD4AE-2744-44FF-9525-127F23C3DFC3 Q35010671-F05D126C-9ACC-4ADD-8451-A15EA6F15A8B Q35026516-8561C258-440A-41F5-8250-C7F756A465C7 Q35028914-1207C541-6687-4017-81BA-40DF42120BEA Q35065740-BD25C1EC-5595-47BE-9F06-1F5CE36DA295 Q35065859-6018D3D6-11E8-491D-90CB-0E6F80A8A30E Q35066649-FAB1CA1C-0FE4-44D5-BAFB-548416F1910A Q35089772-9FA772F4-C78C-45A3-A1AF-7FB3B638DF98 Q35105985-E7700844-DC03-4C47-B72B-518878DAA072

P2860

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

http://www.wikidata.org/entity/Q34006585

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@ast

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@en

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@nl

type

label

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@ast

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@en

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@nl

prefLabel

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@ast

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@en

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@nl

P1433

Q34006585-7C30563E-F9BE-4E2A-9DEF-2384D9DD4505

P1476

Q34006585-ED505A3D-AD67-490C-A030-2EBBD72930C8

P2093

Q34006585-02662727-61E0-4D8D-B304-9A3F035D1EB2

Q34006585-1B88C42C-5B96-474C-92CE-0EFD55B4F0C4

Q34006585-2596E3C2-ED67-4F87-A0D8-AFAB502CEC38

Q34006585-6753036F-8485-4DFB-81CC-CDCCCCA059B2

Q34006585-69276FC2-5527-49BE-B417-933703D4DBF3

Q34006585-74CE565B-FFCB-47EF-9B2F-82E97BF43F30

Q34006585-7B4EFFA8-0FDA-44C5-89EB-69F1B0C27AB0

Q34006585-99B8D36D-6C2E-4FC5-8CBB-855FCF7A5179

Q34006585-A8ACDF46-B0D9-4581-BDDF-E6F746C73189

Q34006585-AAF440A3-3304-4183-96B2-68EB736ED03D

P2860

Q34006585-11E904AC-9F88-437A-B09A-FEB295768136

Q34006585-173D2BA1-4209-4406-B7F7-81E71EE5F169

Q34006585-208351AB-25EB-409C-999C-E7612C5486B4

Q34006585-555E7099-23FE-40C4-9083-8A13BCC4174D

Q34006585-5831B2F4-FC67-4F1C-89E0-206EC275DFBC

Q34006585-660EFCE7-4DD9-4FCB-B43C-1DC7B6CF4548

Q34006585-67A00F3F-0406-49CF-BDDB-B274FD8263E3

Q34006585-6C07827E-7D03-4959-9DD1-F11A4C05A655

Q34006585-7E4BBA1B-EB18-4A5D-9571-0B8060540317

Q34006585-849D797B-1A25-44D9-8059-4E8AF5EAFD8D

P304

Q34006585-A06C0E3C-F75C-4795-9F4C-C932DD95CE6A

P31

Q34006585-BABEDB93-DE08-4CE4-AD68-DEB47377B603

P356

Q34006585-9F703995-FFF8-4441-BAE6-1E59A45504AB

P407

Q34006585-D4A26509-3397-46F8-9FC4-B87633047D24

P433

Q34006585-458EA957-E823-4518-9AE5-8282FBE5B9F3

P478

Q34006585-281D9B3F-B0E3-4476-90B7-8ED3C6D32FCB

P50

Q34006585-C2A029AB-CA9C-4673-AB01-CD2270F3DA1C

P577

Q34006585-9EB1D1F1-1CD4-497B-AAAF-58FF4A55E26B

P5875

Q34006585-C73FDC4B-57C3-4A73-AC78-2543E48910ED

P698

Q34006585-EDA32D61-F185-424D-9851-3DFFFC14F8AC

P356

P1433

Clinical Infectious Diseases

P1476

Micafungin versus caspofungin ...... forms of invasive candidiasis.

@en

P2093

Annette C Reboli

http://www.w3.org/2001/XMLSchema#string

Bertrand F Dupont

http://www.w3.org/2001/XMLSchema#string

Byungse Suh

http://www.w3.org/2001/XMLSchema#string

Chunzhang Wu

http://www.w3.org/2001/XMLSchema#string

Coleman M F Rotstein

http://www.w3.org/2001/XMLSchema#string

David L Horn

http://www.w3.org/2001/XMLSchema#string

Deepak Talwar

http://www.w3.org/2001/XMLSchema#string

Donald N Buell

http://www.w3.org/2001/XMLSchema#string

Jan J De Waele

http://www.w3.org/2001/XMLSchema#string

Jose A Vazquez

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Epidemiology of invasive candidiasis: a persistent public health problem

Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance.

Anidulafungin versus fluconazole for invasive candidiasis.

The changing face of fungal infections in health care settings.

Echinocandin antifungals: review and update.

Emerging echinocandins for treatment of invasive fungal infections.

Anidulafungin: a novel echinocandin.

P304

883-893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/520980

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6034580

http://www.w3.org/2001/XMLSchema#string

P698

17806055

http://www.w3.org/2001/XMLSchema#string